Fact-check: Johns Hopkins Medicine's podcast on how GLP-1s work and who they help

What the video covers

Dr. Selvi Rajagopal, who directs the Healthful Eating, Activity and Weight Program at Johns Hopkins, talks with the Division of General Internal Medicine's podcast hosts about how weight and body composition change with age, how she sets goals with patients, where GLP-1 medications fit, what the first weeks on one feel like, and how she answers the question about compounded products.

What it gets right

The body-composition framing is the most valuable part. Lean mass declines with each decade after early adulthood, faster after 40 and around menopause, and because muscle is the main site of resting energy expenditure that decline lowers energy needs. That is standard physiology, and it sets up the later point that any weight loss should be paired with protein and resistance training to limit muscle loss.

The efficacy framing is fair. She says lifestyle intervention alone typically achieves 5 to 8 percent and that holding 10 percent or more is exceedingly hard. The Look AHEAD trial, the largest structured lifestyle program in type 2 diabetes, produced 8.6 percent at one year and 6.2 percent at four years in the intensive arm (PubMed 20876408), which is the right order of magnitude. GLP-1 medications are, in her words, "a bit more potent": STEP 1 gives 14.9 percent for semaglutide 2.4 mg at 68 weeks (PubMed 33567185).

Her side-effect description matches the labels: gastrointestinal effects in the early weeks and after each dose increase, mostly nausea, sometimes constipation or diarrhoea, improving as the body adapts. Her statin analogy for continuing the drug is the same conclusion the withdrawal trials reached.

What it leaves out or overstates

Because it is a conversation, numbers are approximate and nothing is cited on air. "Almost 90 percent" of patients experiencing some GI effect is higher than the 74 percent reported in STEP 1 but consistent with her clinical population; treat it as an estimate. The advice not to lose more than about two pounds a week is a common clinical rule of thumb rather than a trial-derived threshold.

The compounding section needs the most care. She describes two kinds of compounders, one with FDA oversight of the facility (503B outsourcing facilities) and one without (503A pharmacies), and says the FDA has stated that compounding these drugs is no longer permitted now the shortage is over. That is accurate as of the recording: the FDA declared the semaglutide shortage resolved on 21 February 2025 and tirzepatide's on 19 December 2024, and its enforcement-discretion periods for compounders ended in the following months. Compounders may still prepare a drug for an individual patient when there is a documented clinical need the approved product cannot meet, which is the basis on which some pharmacies continue. Whatever the basis, compounded semaglutide and tirzepatide are not FDA approved, are not checked by the FDA for safety, effectiveness or quality, and are not interchangeable with brand products. FormBlends dispenses compounded GLP-1s through licensed pharmacies and discloses that interest here.

Where to go next

The Endocrine Society podcast in the side-effects playlist covers compounding in more depth. For the regulatory detail, Compounding Explained walks through 503A versus 503B and how to check a pharmacy licence. For protein targets during weight loss, use the calculator on Weight Loss on GLP-1s. The FormBlends tirzepatide guide is at formblends.com.